The Monday Brief — Week of Jul 26, 2026

Galderma posted $3.134B in H1 2026 net sales, a 24.6% year-on-year jump, and raised full-year guidance. The surge is driven by Nemluvio (rosacea), Dysport, and the GLP-1 weight-loss effect—patients on semaglutide and tirzepatide are seeking facial rejuvenation to address volume loss and skin laxity. This isn't a temporary spike; it's a structural shift in demand. For independent practices, the message is clear: scale matters. Galderma's size lets it absorb supply chain friction and invest in direct sales forces. Smaller players and regional brands are racing to keep pace, but margin pressure is real.

AbbVie's Boey—a rapid-onset, short-duration botulinum toxin—won EU approval this week. It's positioned as a faster alternative to traditional Botox, appealing to patients who want results in hours rather than days. The product also landed in the U.S. earlier this year. Speed of onset and duration are now active competitive vectors in injectables. Owners should monitor how Boey gains traction in their markets and whether patient demand for "quick-acting" options justifies inventory and training investment. Allergan is betting on differentiation; the field will tell if it sticks.

South Korea's Hugel launched Letybo (botulinum toxin) in the U.S. with a direct sales force and is running a K-TOX campaign to build brand awareness. Simultaneously, Hugel entered India with Letybo, targeting 9% market share by 2026. This is classic regional-to-global playbook: build scale at home, then expand via direct sales and aggressive marketing. Hugel also officially launched in India this period. For U.S. owners, this signals rising competition from well-capitalized Asian manufacturers. Letybo will compete on price and claims; practices should expect more direct outreach from Hugel reps.

Multiple sources confirm that GLP-1 weight-loss drugs (semaglutide, tirzepatide) are driving a secondary demand surge for facial rejuvenation. Patients losing weight rapidly experience volume loss, skin laxity, and jowling—classic triggers for fillers, threads, and skin tightening. Bridal shops in Iowa are reporting brides on GLP-1s seeking cosmetic procedures before weddings. Galderma's H1 beat is partly fueled by this trend. Owners should expect sustained demand for volumization, skin tightening, and non-invasive lifting through 2026 and beyond. Train your team to recognize and address GLP-1–related aesthetic concerns; it's a new patient acquisition vector.

AbbVie sued Galderma over patented dermal filler syringe designs—a sign of intensifying IP competition as the market consolidates. Separately, InMode's board is evaluating rival acquisition offers, including a $16.75-per-share buyout proposal from Steel Partners. These moves reflect the sector's appetite for consolidation and the premium placed on proprietary technology and distribution. Owners should monitor M&A activity; it affects product availability, pricing, and rep relationships. If your key suppliers or competitors are acquired, expect operational and contractual changes.

Galderma launched Alastin (regenerative skincare) across Japan and key Asia-Pacific markets. Skincare is increasingly bundled with injectables and devices as a full-face rejuvenation strategy. Owners who offer complementary skincare lines (pre- and post-procedure) are capturing higher lifetime patient value. Alastin's expansion signals that Galderma sees skincare as a margin-accretive, sticky revenue stream. If you haven't integrated a skincare line into your practice, this is a reminder that injectables alone are no longer the full story.